Haris Ali

3.0k total citations
101 papers, 953 citations indexed

About

Haris Ali is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Haris Ali has authored 101 papers receiving a total of 953 indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Hematology, 51 papers in Genetics and 18 papers in Oncology. Recurrent topics in Haris Ali's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (41 papers), Acute Myeloid Leukemia Research (41 papers) and Chronic Myeloid Leukemia Treatments (34 papers). Haris Ali is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (41 papers), Acute Myeloid Leukemia Research (41 papers) and Chronic Myeloid Leukemia Treatments (34 papers). Haris Ali collaborates with scholars based in United States, Canada and Italy. Haris Ali's co-authors include Ryotaro Nakamura, Stephen J. Forman, Amandeep Salhotra, Monzr M. Al Malki, Mark A. Schroeder, Miguel‐Angel Perales, Yi‐Bin Chen, Madan Jagasia, Michael Arbushites and Guido Marcucci and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Haris Ali

93 papers receiving 946 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Haris Ali United States 15 701 331 241 227 166 101 953
Édouard Forcade France 18 674 1.0× 195 0.6× 372 1.5× 441 1.9× 138 0.8× 105 1.2k
Roni Tamari United States 18 601 0.9× 205 0.6× 99 0.4× 278 1.2× 161 1.0× 98 977
Filippo Ballerini Italy 14 662 0.9× 224 0.7× 138 0.6× 245 1.1× 232 1.4× 55 825
Arjun Law Canada 17 619 0.9× 150 0.5× 275 1.1× 391 1.7× 119 0.7× 142 1.0k
Kazutaka Sunami Japan 18 667 1.0× 222 0.7× 182 0.8× 530 2.3× 368 2.2× 115 1.2k
Samer K. Khaled United States 20 589 0.8× 174 0.5× 208 0.9× 198 0.9× 240 1.4× 65 950
Viviane Dubruille France 20 872 1.2× 605 1.8× 127 0.5× 405 1.8× 214 1.3× 68 1.4k
Brian C. Betts United States 21 578 0.8× 151 0.5× 614 2.5× 390 1.7× 196 1.2× 68 1.2k
Kris Doney United States 14 756 1.1× 202 0.6× 275 1.1× 214 0.9× 80 0.5× 18 902
Wolfram Pönisch Germany 15 806 1.1× 179 0.5× 218 0.9× 243 1.1× 198 1.2× 62 1.0k

Countries citing papers authored by Haris Ali

Since Specialization
Citations

This map shows the geographic impact of Haris Ali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haris Ali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haris Ali more than expected).

Fields of papers citing papers by Haris Ali

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haris Ali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haris Ali. The network helps show where Haris Ali may publish in the future.

Co-authorship network of co-authors of Haris Ali

This figure shows the co-authorship network connecting the top 25 collaborators of Haris Ali. A scholar is included among the top collaborators of Haris Ali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haris Ali. Haris Ali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Patnaik, Mrinal M., Haris Ali, Eunice S. Wang, et al.. (2025). Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study. PubMed. 2(4). 100115–100115.
2.
Amanam, Idoroenyi, Salman Otoukesh, Vinod Pullarkat, et al.. (2025). Myelofibrosis-associated extramedullary hematopoiesis: Insights into hepatic, pulmonary, and thrombotic complications. Blood Reviews. 75. 101355–101355.
3.
Ngo, Dat, et al.. (2024). Hypomethylating Agents are Effective in Treatment for Relapsed Myelofibrosis After Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 30(11). 1091.e1–1091.e8. 1 indexed citations
4.
5.
Wong, Jeffrey Y.C., Amandeep Salhotra, Savita Dandapani, et al.. (2024). Phase II Trial of TMLI 20 Gy in Combination with Cyclophosphamide and Etoposide in Patients with Poor-Risk Acute Leukemia. International Journal of Radiation Oncology*Biology*Physics. 120(2). S90–S91.
6.
Tantravahi, Srinivas K., Ashwin Kishtagari, Sanjay Mohan, et al.. (2024). MPN-527 Selinexor and Ruxolitinib Impact on Symptom Burden in Patients With Myelofibrosis Is Potentially Driven by Inhibition of NF-κB and Activation of P53 Pathways. Clinical Lymphoma Myeloma & Leukemia. 24. S437–S438. 1 indexed citations
7.
Frankhouser, David, Russell C. Rockne, Dandan Zhao, et al.. (2024). State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia. Leukemia. 38(4). 769–780. 2 indexed citations
8.
Zhang, Jianying, Vinod Pullarkat, Vaibhav Agrawal, et al.. (2024). Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer. British Journal of Haematology. 205(1). 158–165. 1 indexed citations
9.
10.
Ali, Haris & Andrea Bacigalupo. (2024). 2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. American Journal of Hematology. 99(5). 938–945. 10 indexed citations
11.
Fei, Fei, Amar Jariwala, Sheeja T. Pullarkat, et al.. (2024). Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study. International Journal of Molecular Sciences. 25(18). 10214–10214. 3 indexed citations
12.
Mehta, Rohtesh S., Haris Ali, Voravit Ratanatharathorn, et al.. (2023). A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement. Bone Marrow Transplantation. 58(9). 991–999. 5 indexed citations
13.
Salhotra, Amandeep, Shan Yuan, & Haris Ali. (2023). Fifty years of BMT: risk stratification, donor matching, and stem cell collection for transplantation. Frontiers in Oncology. 13. 1196564–1196564. 2 indexed citations
14.
Malki, Monzr M. Al, Joycelynne Palmer, Ni‐Chun Tsai, et al.. (2022). Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. Blood Advances. 6(14). 4098–4106. 15 indexed citations
15.
Zhao, Dandan, Le Xuan Truong Nguyen, Fang Chen, et al.. (2021). Spred1 deficit promotes treatment resistance and transformation of chronic phase CML. Leukemia. 36(2). 492–506. 5 indexed citations
16.
Otoukesh, Salman, Hany Elmariah, Dongyun Yang, et al.. (2021). Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplantation and Cellular Therapy. 28(2). 111.e1–111.e8. 12 indexed citations
17.
Malki, Monzr M. Al, Ni‐Chun Tsai, Joycelynne Palmer, et al.. (2021). Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. Blood Advances. 5(12). 2650–2659. 32 indexed citations
18.
Yao, Janny M., Dongyun Yang, Mary C. Clark, et al.. (2021). Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. Bone Marrow Transplantation. 57(2). 232–242. 3 indexed citations
19.
Schroeder, Mark A., H. Jean Khoury, Madan Jagasia, et al.. (2020). A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Blood Advances. 4(8). 1656–1669. 72 indexed citations
20.
Aldoss, Ibrahim, Jianying Zhang, Matthew Mei, et al.. (2020). Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia. American Journal of Hematology. 95(10). 1193–1199. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Édouard Forcade Breakdown of academic impact, for papers by Roni Tamari Breakdown of academic impact, for papers by Filippo Ballerini Breakdown of academic impact, for papers by Arjun Law Breakdown of academic impact, for papers by Kazutaka Sunami Breakdown of academic impact, for papers by Samer K. Khaled Breakdown of academic impact, for papers by Viviane Dubruille Breakdown of academic impact, for papers by Brian C. Betts Breakdown of academic impact, for papers by Kris Doney Breakdown of academic impact, for papers by Wolfram Pönisch
Rankless by CCL
2026